Clinical Trial Update: An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer

View source ↗

Summary

Eisai's lenvatinib expanded access program for radioiodine-refractory differentiated thyroid cancer has resulted in marketing approval for this indication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Differentiated Thyroid Cancer

Drugs mentioned

• LENVIMA (lenvatinib)

Snippet

Sponsor: Eisai Inc. | Conditions: Differentiated Thyroid Cancer | Status: APPROVED_FOR_MARKETING